JMP Securities Reiterates Market Outperform Rating for Evolent Health (NYSE:EVH)

JMP Securities reissued their market outperform rating on shares of Evolent Health (NYSE:EVH - Free Report) in a research note released on Monday,Benzinga reports. JMP Securities currently has a $13.00 price target on the technology company's stock.

A number of other analysts also recently issued reports on EVH. Oppenheimer decreased their price objective on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a report on Friday, January 24th. Stephens lowered their price target on shares of Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a report on Tuesday, January 21st. Citigroup reduced their price objective on Evolent Health from $21.00 to $18.00 and set a "buy" rating for the company in a report on Friday, January 10th. UBS Group dropped their price target on Evolent Health from $27.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, January 16th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $15.00 price objective on shares of Evolent Health in a report on Friday, February 21st. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $17.71.

Evolent Health Stock Up 7.8 %

NYSE:EVH traded up $0.78 on Monday, hitting $10.73. The stock had a trading volume of 1,747,176 shares, compared to its average volume of 2,368,507. Evolent Health has a 1 year low of $8.35 and a 1 year high of $33.63. The firm's fifty day simple moving average is $9.48 and its two-hundred day simple moving average is $12.11. The stock has a market cap of $1.25 billion, a P/E ratio of -13.09 and a beta of 1.20. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Evolent Health (NYSE:EVH - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). The business had revenue of $646.54 million for the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. Analysts predict that Evolent Health will post 0.08 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Brendan B. Springstubb bought 5,000 shares of Evolent Health stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $8.75 per share, with a total value of $43,750.00. Following the completion of the purchase, the director now directly owns 11,842 shares in the company, valued at $103,617.50. The trade was a 73.08 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Diane Holder purchased 2,735 shares of the stock in a transaction on Thursday, March 6th. The shares were purchased at an average price of $9.33 per share, for a total transaction of $25,517.55. Following the transaction, the director now directly owns 70,584 shares of the company's stock, valued at approximately $658,548.72. This represents a 4.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 74,000 shares of company stock worth $666,315 over the last ninety days. 1.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Pilgrim Partners Asia Pte Ltd purchased a new position in Evolent Health in the 4th quarter worth approximately $26,000. R Squared Ltd bought a new position in shares of Evolent Health during the fourth quarter valued at about $31,000. AlphaQuest LLC boosted its holdings in shares of Evolent Health by 21,650.0% during the fourth quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock worth $34,000 after purchasing an additional 3,031 shares during the period. Parkside Financial Bank & Trust increased its holdings in Evolent Health by 90.7% during the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock valued at $56,000 after purchasing an additional 2,358 shares during the period. Finally, AlphaCentric Advisors LLC bought a new position in Evolent Health during the 4th quarter valued at approximately $61,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.